title: [Influence of chronic cardiac failure severity on the course of comorbid type 2 diabetes mellitus].
abstract: OBJECTIVE
  To assess relations between severity of chronic cardiac failure (CCF) and a course of comorbid type 2 diabetes mellitus (DM).
  
  
  METHODS
  Time course changes of cerebral natriuretic peptide (CNUP) were used as a criterion of CCF severity in 81 patients with mild and moderate CCF (NYHA functional class II-III), left ventricular ejection fraction (LVEF) < 45% and type 2 DM. Of them, two groups of 19 patients each were compiled--with the highest and lowest CNUP levels. Also, patients with a rising CNUP level and CCF FC (n = 5) and those with decreasing CNUP and FC improvement (n = 33) were analysed. The following parameters were studied at baseline and 6 months later: clinicofunctional status, glomerular filtration rate (GFR), neurohormonal profile (CNUP), noradrenalin and angiotensin II, the level of HbA1c, baseline and postprandial plasma glucose, serum insulin and C-peptide.
  
  
  RESULTS
  Insignificant changes in glycemia in low C-peptide were found in groups with mild CCF. In patients with high CNUP and CCF FC there was a positive correlation between high CNUP, noradrenalin and fasting glucose. With growing severity of CCF clinicofunctional status of the patients was deteriorating while levels of noradrenalin and angiotensin II tended to rise.
  
  
  CONCLUSIONS
  Moderate decompensation of CCF had no effect on the course of associated DM. More severe and long-term decompensation may be accompanied with noticeable changes in glycemia.
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Narusov
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Lapina
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Mareev
authors.forename: M G
authors.initials: MG
authors.lastname: Bolotina
authors.forename: M V
authors.initials: MV
authors.lastname: Shestakova
authors.forename: V P
authors.initials: VP
authors.lastname: Masenko
authors.forename: N A
authors.initials: NA
authors.lastname: Baklanova
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Belenkov
mesh_terms: D000368:Aged; D000804:Angiotensin II / Q000097:blood; D002096:C-Peptide / Q000097:blood; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009638:Norepinephrine / Q000097:blood; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D002096:C-Peptide; D007328:Insulin; D000804:Angiotensin II; D020097:Natriuretic Peptide, Brain; D009638:Norepinephrine